296 related articles for article (PubMed ID: 24323899)
1. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
[TBL] [Abstract][Full Text] [Related]
2. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
Weide B; Zelba H; Derhovanessian E; Pflugfelder A; Eigentler TK; Di Giacomo AM; Maio M; Aarntzen EH; de Vries IJ; Sucker A; Schadendorf D; Büttner P; Garbe C; Pawelec G
J Clin Oncol; 2012 May; 30(15):1835-41. PubMed ID: 22529253
[TBL] [Abstract][Full Text] [Related]
3. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.
Zelba H; Weide B; Martens A; Derhovanessian E; Bailur JK; Kyzirakos C; Pflugfelder A; Eigentler TK; Di Giacomo AM; Maio M; Aarntzen EH; de Vries J; Sucker A; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Aug; 20(16):4390-9. PubMed ID: 24938524
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
5. Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?
Martens A; Zelba H; Garbe C; Pawelec G; Weide B
Oncoimmunology; 2014 Jan; 3(1):e27845. PubMed ID: 24800171
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
[TBL] [Abstract][Full Text] [Related]
8. T cells targeting NY-ESO-1 and Melan-A are prognostic in melanoma.
Cancer Discov; 2012 Jun; 2(6):OF7. PubMed ID: 22684465
[TBL] [Abstract][Full Text] [Related]
9. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
[TBL] [Abstract][Full Text] [Related]
11. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
12. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
[TBL] [Abstract][Full Text] [Related]
13. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Tarhini AA; Edington H; Butterfield LH; Lin Y; Shuai Y; Tawbi H; Sander C; Yin Y; Holtzman M; Johnson J; Rao UN; Kirkwood JM
PLoS One; 2014; 9(2):e87705. PubMed ID: 24498358
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.
Klein O; Davis ID; McArthur GA; Chen L; Haydon A; Parente P; Dimopoulos N; Jackson H; Xiao K; Maraskovsky E; Hopkins W; Stan R; Chen W; Cebon J
Cancer Immunol Immunother; 2015 Apr; 64(4):507-18. PubMed ID: 25662405
[TBL] [Abstract][Full Text] [Related]
15. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
16. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.
Najjar YG; Ding F; Lin Y; VanderWeele R; Butterfield LH; Tarhini AA
J Transl Med; 2017 Feb; 15(1):39. PubMed ID: 28222797
[TBL] [Abstract][Full Text] [Related]
17. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.
Ebert LM; MacRaild SE; Zanker D; Davis ID; Cebon J; Chen W
PLoS One; 2012; 7(10):e48424. PubMed ID: 23110239
[TBL] [Abstract][Full Text] [Related]
18. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Khong HT; Yang JC; Topalian SL; Sherry RM; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2004; 27(6):472-7. PubMed ID: 15534491
[TBL] [Abstract][Full Text] [Related]
19. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.
Fourcade J; Sun Z; Kudela P; Janjic B; Kirkwood JM; El-Hafnawy T; Zarour HM
J Immunol; 2010 Jun; 184(12):6709-18. PubMed ID: 20483736
[TBL] [Abstract][Full Text] [Related]
20. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]